161 related articles for article (PubMed ID: 33470543)
21. Synthesis and evaluation of 3-amino/guanidine substituted phenyl oxazoles as a novel class of LSD1 inhibitors with anti-proliferative properties.
Dulla B; Kirla KT; Rathore V; Deora GS; Kavela S; Maddika S; Chatti K; Reiser O; Iqbal J; Pal M
Org Biomol Chem; 2013 May; 11(19):3103-7. PubMed ID: 23575971
[TBL] [Abstract][Full Text] [Related]
22. Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation.
Fioravanti R; Romanelli A; Mautone N; Di Bello E; Rovere A; Corinti D; Zwergel C; Valente S; Rotili D; Botrugno OA; Dessanti P; Vultaggio S; Vianello P; Cappa A; Binda C; Mattevi A; Minucci S; Mercurio C; Varasi M; Mai A
ChemMedChem; 2020 Apr; 15(7):643-658. PubMed ID: 32003940
[TBL] [Abstract][Full Text] [Related]
23. Heterocycle-containing tranylcypromine derivatives endowed with high anti-LSD1 activity.
Fioravanti R; Rodriguez V; Caroli J; Chianese U; Benedetti R; Di Bello E; Noce B; Zwergel C; Corinti D; Viña D; Altucci L; Mattevi A; Valente S; Mai A
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):973-985. PubMed ID: 35317680
[TBL] [Abstract][Full Text] [Related]
24. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
[TBL] [Abstract][Full Text] [Related]
25. Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
Rotili D; Tomassi S; Conte M; Benedetti R; Tortorici M; Ciossani G; Valente S; Marrocco B; Labella D; Novellino E; Mattevi A; Altucci L; Tumber A; Yapp C; King ON; Hopkinson RJ; Kawamura A; Schofield CJ; Mai A
J Med Chem; 2014 Jan; 57(1):42-55. PubMed ID: 24325601
[TBL] [Abstract][Full Text] [Related]
26. New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.
Hoang N; Zhang X; Zhang C; Vo V; Leng F; Saxena L; Yin F; Lu F; Zheng G; Bhowmik P; Zhang H
Bioorg Med Chem; 2018 May; 26(8):1523-1537. PubMed ID: 29439916
[TBL] [Abstract][Full Text] [Related]
27. Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity.
Suzuki T; Ozasa H; Itoh Y; Zhan P; Sawada H; Mino K; Walport L; Ohkubo R; Kawamura A; Yonezawa M; Tsukada Y; Tumber A; Nakagawa H; Hasegawa M; Sasaki R; Mizukami T; Schofield CJ; Miyata N
J Med Chem; 2013 Sep; 56(18):7222-31. PubMed ID: 23964788
[TBL] [Abstract][Full Text] [Related]
28. Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
Naveen Sadhu M; Sivanandhan D; Gajendran C; Tantry S; Dewang P; Murugan K; Chickamunivenkatappa S; Zainuddin M; Nair S; Vaithilingam K; Rajagopal S
Bioorg Med Chem Lett; 2021 Feb; 34():127763. PubMed ID: 33359604
[TBL] [Abstract][Full Text] [Related]
29. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
30. Structure-based design and discovery of potent and selective KDM5 inhibitors.
Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
[TBL] [Abstract][Full Text] [Related]
31. Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.
Duan YC; Guan YY; Zhai XY; Ding LN; Qin WP; Shen DD; Liu XQ; Sun XD; Zheng YC; Liu HM
Eur J Med Chem; 2017 Jan; 126():246-258. PubMed ID: 27888721
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and molecular docking studies of thymol based 1,2,3-triazole hybrids as thymidylate synthase inhibitors and apoptosis inducers against breast cancer cells.
Alam MM; Malebari AM; Syed N; Neamatallah T; Almalki ASA; Elhenawy AA; Obaid RJ; Alsharif MA
Bioorg Med Chem; 2021 May; 38():116136. PubMed ID: 33894490
[TBL] [Abstract][Full Text] [Related]
33. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
[TBL] [Abstract][Full Text] [Related]
34. Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors.
Benelkebir H; Hodgkinson C; Duriez PJ; Hayden AL; Bulleid RA; Crabb SJ; Packham G; Ganesan A
Bioorg Med Chem; 2011 Jun; 19(12):3709-16. PubMed ID: 21382717
[TBL] [Abstract][Full Text] [Related]
35. Design, Synthesis, and Preliminary Bioactivity Evaluation of 2,7-Substituted Carbazole Derivatives as Potent Autotaxin Inhibitors and Antitumor Agents†.
Wang W; Zhao F; Zhao Y; Pan W; Cao P; Wu L; Wang Z; Zhao X; Zhao Y; Wang H
Anticancer Agents Med Chem; 2019; 19(2):256-264. PubMed ID: 30173652
[TBL] [Abstract][Full Text] [Related]
36. Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity.
Schmitt ML; Hauser AT; Carlino L; Pippel M; Schulz-Fincke J; Metzger E; Willmann D; Yiu T; Barton M; Schüle R; Sippl W; Jung M
J Med Chem; 2013 Sep; 56(18):7334-42. PubMed ID: 24007511
[TBL] [Abstract][Full Text] [Related]
37. Design, Synthesis, and Biological Evaluation of a Conjugate of 5-Fluorouracil and an LSD1 Inhibitor.
Ota Y; Nakamura A; Elboray EE; Itoh Y; Suzuki T
Chem Pharm Bull (Tokyo); 2019 Mar; 67(3):192-195. PubMed ID: 30369513
[TBL] [Abstract][Full Text] [Related]
38. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.
Westaway SM; Preston AG; Barker MD; Brown F; Brown JA; Campbell M; Chung CW; Drewes G; Eagle R; Garton N; Gordon L; Haslam C; Hayhow TG; Humphreys PG; Joberty G; Katso R; Kruidenier L; Leveridge M; Pemberton M; Rioja I; Seal GA; Shipley T; Singh O; Suckling CJ; Taylor J; Thomas P; Wilson DM; Lee K; Prinjha RK
J Med Chem; 2016 Feb; 59(4):1370-87. PubMed ID: 26771203
[TBL] [Abstract][Full Text] [Related]
39. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures.
Ota Y; Kakizawa T; Itoh Y; Suzuki T
Molecules; 2018 May; 23(5):. PubMed ID: 29734782
[TBL] [Abstract][Full Text] [Related]
40. Identification of fenoldopam as a novel LSD1 inhibitor to abrogate the proliferation of renal cell carcinoma using drug repurposing strategy.
Zheng Y; Ma Y; Cao H; Yan L; Gu Y; Ren X; Jiao X; Wan S; Shao F
Bioorg Chem; 2021 Mar; 108():104561. PubMed ID: 33349457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]